Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Staphylococcus is a genus of Gram-positive, non-motile bacteria that appear as spherical cocci in grape-like clusters under microscopic examination (StatPearls, 2023). While these organisms are frequently found as commensals on human skin and mucous membranes, they are also formidable opportunistic pathogens capable of causing a wide range of diseases from superficial abscesses to life-threatening systemic infections like sepsis and endocarditis (NIH, 2022). From a pharmacological perspective, 'Staphylococcal bacteria' refers to a whole pathogen genus rather than a specific molecular target like a receptor or enzyme; drugs instead target essential bacterial components such as Penicillin-Binding Proteins or the bacterial ribosome (PubMed, 2021). The clinical management of these infections is severely challenged by the prevalence of antibiotic resistance, particularly in strains like Methicillin-resistant Staphylococcus aureus (MRSA), which necessitates the use of specialized, often more toxic, antibiotic therapies (CDC, 2019). Ongoing research focuses on identifying novel targets within the bacterial cell to circumvent existing resistance mechanisms and biofilm-related survival strategies (Nature Reviews Microbiology, 2018).
Antibacterial agents targeting Staphylococcus species function through various mechanisms, including the inhibition of cell wall peptidoglycan synthesis (e.g., beta-lactams and glycopeptides), inhibition of protein synthesis by binding to the 50S or 30S ribosomal subunits (e.g., linezolid, clindamycin), or disruption of the bacterial cell membrane (e.g., daptomycin) (StatPearls, 2023; NIH, 2022).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Staphylococcus.